Tag: Diagnostics

Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic disease which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged

It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. It is also worth highlighting that companion diagnostics (CDX) guided drug development efforts have been estimated to help reduce clinical trial costs by almost 60%. Since the approval of the HercepTest (in 1998) for identifying patients for treatment

Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030’ report provides a